Adam Koppel - 16 Oct 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role: Director, 10%+ Owner
Signature: /s/ Adam Koppel
Issuer symbol: N/A
Transactions as of: 16 Oct 2023
Net transactions value: +$124,999,986
Form type: 4
Filing time: 18 Oct 2023, 16:30:12 UTC
Previous filing: 22 Jun 2023
Next filing: 12 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Purchase	$124,999,986	+5,480,052	+9.1%	$22.81	65,679,781	16 Oct 2023	See footnotes	F1, F2
holding	CERE	Common Stock						3,282	16 Oct 2023	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of the Issuer's common stock held directly by BC Perception Holdings, LP ("BC Perception"). Adam Koppel is a Partner of Bain Capital Life Sciences Investors, LLC. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Dr. Koppel disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.
F2	On October 16, 2023, BC Perception purchased 5,480,052 shares of the Issuer's common stock at a price of $22.81 per share in an underwritten public offering.

Content

Represents shares of the Issuer's common stock held directly by BC Perception Holdings, LP ("BC Perception"). Adam Koppel is a Partner of Bain Capital Life Sciences Investors, LLC. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Dr. Koppel disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.

On October 16, 2023, BC Perception purchased 5,480,052 shares of the Issuer's common stock at a price of $22.81 per share in an underwritten public offering.